Lazertinib?

What is lazertinib?

Lazertinib is described as an investigational EGFR inhibitor associated with use in EGFR-driven non-small cell lung cancer (NSCLC). It is listed among cancer medicines/clinical research entries that involve EGFR-targeted therapy. [1]

What type of cancer is lazertinib for?

Entries that mention lazertinib place it in the context of EGFR-related lung cancer treatment development, specifically non-small cell lung cancer where EGFR mutations can drive tumor growth. [1]

Is lazertinib FDA- or EMA-approved?

The provided material only identifies lazertinib as an item in a cancer drug/clinical research listing; it does not state approval status by the FDA or EMA. [1]

How does it work (what is the target)?

Lazertinib is categorized as an EGFR inhibitor, meaning its intended mechanism is blocking EGFR signaling in tumors that depend on EGFR activity. [1]

Where can I find more details (clinical trials, dosing, results)?

The provided source points to a general listing page for lazertinib but does not include trial-by-trial details (such as dosing schedules or efficacy endpoints) in the text you provided. [1]

Sources:
[1] https://www.cancer.gov/about-cancer/treatment/drugs/lazertinib